All News

Investigators also report an improvement in time to next intervention with vorasidenib compared with placebo among patients with IDH-mutated glioma in the phase 3 INDIGO trial.

Results from the phase 1/2 BEXMAB study assessing bexmarilimab show promising activity in patients with acute myeloid leukemia.

Data from the phase 3 KEYNOTE-811 trial highlight a trend towards improved overall survival among patients with HER2-positive, PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma receiving pembrolizumab, trastuzumab, and chemotherapy.

Findings from a multi-center phase 1/2 trial highlight only that only grade 1 cytokine release syndrome events occurred among patients with indolent non-Hodgkin lymphoma receiving MB-106.

Lucio N. Gordan, MD, also discusses how increasing domestic manufacturing of chemotherapy may help in alleviating the ongoing shortages of carboplatin and cisplatin in the United States.

Treatment with divarasib appears to produce a manageable safety profile of low-grade toxicities in patients with advanced or metastatic KRAS G12C–mutated solid tumors.

Increasing radiation doses to the whole heart appear to correlate with higher risks of valvular disease, coronary artery disease, and heart failure in childhood cancer survivors.

Data from the phase 3 THOR study support the supplemental biologics license application for erdafitinib in previously treated advanced or metastatic urothelial carcinoma with FGFR3 alterations.

Luspatercept, the use of which is supported by results from the phase 3 COMMANDS trial presented at 2023 ASCO, is now available for patients with low-risk myelodysplastic syndrome and anemia.

Luspatercept, which is now FDA approved for myelodysplastic syndromes, may help patients achieve transfusion independence.

Findings from an exploratory subgroup analysis in the phase 3 INNOVATE-3 trial suggest that Tumor Treating Fields plus paclitaxel may confer a survival benefit in patients who received only 1 prior line of therapy for platinum-resistant ovarian cancer.

Updated findings from the phase 3 TROPiCS-02 trial support sacituzumab govitecan as a standard treatment for hormone receptor–positive, HER2-negative breast cancer, according to Sara Tolaney, MD, MPH.

The safety profile of cabozantinib as a treatment for patients with advanced pancreatic neuroendocrine tumors in the phase 3 CABINET trial is comparable with previous reports of the agent.

Findings from the phase 1/2 MajesTEC-1 study support the European Commission’s approval of teclistamab at a reduced dose frequency for patients with relapsed/refractory multiple myeloma.

Investigators of a prospective study of 1253 patients find that outcomes with the experimental homoharringtonine-based regimen either meet or exceed those with a classic etoposide-based regimen.

When combined with brain stereotactic radiosurgery, trastuzumab emtansine appears to produce minimal acute skin effects among patients with non-metastatic breast cancer.

At an Around the Practice, experts from Emory University gathered to discuss treatment options for patients with multiple myeloma who are transplant-eligible or ineligible.

Patients with complete lymph node response, partial lymph node response, or negative lymph node response were less likely to experience recurrence and increased survival in esophageal adenocarcinoma.

Patients who are already enrolled on clinical trials assessing magrolimab in acute myeloid leukemia are eligible to continue treatment with the agent.

Data from the phase 3 PAPILLON trial support the supplemental biologics license application for amivantamab plus chemotherapy as a treatment for EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

Positive data from a prespecified interim efficacy analysis of the phase 3 LIBRETTO-531 trial support selpercatinib as a potential treatment in advanced, RET-mutant medullary thyroid cancer.

Data indicate that replacement of vincristine with polatuzumab vedotin in combination with etoposide, prednisone, cyclophosphamide, doxorubicin, and rituximab should be further explored in large B-cell lymphoma.

Investigators will assess the safety and pharmacodynamics of ALE.C04 in patients with CLDN1-positive head and neck squamous cell carcinoma as part of a phase 1/2 clinical trial.

Findings from a real-world study highlight that treatment utilization, such as agents for managing tumor lysis syndrome, appears to be more intense when older patients with chronic lymphocytic leukemia initiate treatment with venetoclax plus obinutuzumab.

Data from the phase 3 CheckMate-76k trial support the European Commission’s approval of nivolumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma.

Data from the phase 1 ELM-1 trial and phase 2 ELM-2 trial support the marketing authorization application for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.

The primary end point of progression-free survival was met in the phase 3 LITESPARK-005 trial investigating belzutifan vs everolimus in patients with renal cell carcinoma.

Data from a next-generation sequencing analysis indicate that XPO1 may be a novel biomarker predictive of a decreased time to first treatment in patients with early-stage chronic lymphocytic leukemia.

The FDA sets a Prescription Drug User Fee Act date in the fourth quarter of 2023 for its decision regarding enzalutamide as a treatment for those with non-metastatic hormone-sensitive prostate cancer with a high-risk of biochemical recurrence.